Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00372827
First received: September 6, 2006
Last updated: April 5, 2012
Last verified: May 2008

September 6, 2006
April 5, 2012
February 2004
January 2006   (final data collection date for primary outcome measure)
Mean diurnal intraocular pressure at month 3
Same as current
Complete list of historical versions of study NCT00372827 on ClinicalTrials.gov Archive Site
  • Individual intraocular pressures measured at 08:00, 12:00 and 16:00 at month 3.
  • Reduction from baseline in mean diurnal intraocular pressure and individual timepoints.
  • Visual acuity, Slit lamp biomicroscopy and adverse events during 3 months.
Same as current
Not Provided
Not Provided
 
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension

The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Primary Open-angle Glaucoma
  • Ocular Hypertension
  • Pigment Dispersion Glaucoma
Drug: Brinzolamide 1% added to Travoprost 0.004%
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
245
January 2006
January 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who are treated with any prostaglandin analogue monotherapy (excluding unoprostone) and who have an intraocular pressure between 19 and 32 mmHg at 08:00 hours.

Exclusion Criteria:

  • Under 18 years
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00372827
CM-03-06
Not Provided
Alcon Research
Alcon Research
Not Provided
Study Director: Anna Grau Study Manager
Alcon Research
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP